A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes

Phase 1 Completed 25 enrolled Kallyope Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 and K-833 when co-administered in overweight/obese patients with Type 2 diabetes mellitus (T2DM)

Timeline

Start: 2023-12-07
Primary completion: 2024-05-15
Completion: 2024-06-21

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	K-757	Unknown	—	Oral
Subject	K-833	Unknown	—	Oral

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes

Summary

Timeline

Drugs

Indications